NCT03284931View on ClinicalTrials.gov

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

December 4, 2017

Study Completion Date

December 18, 2017

Conditions

Healthy

Interventions

DRUG

SAGE-217 high dose

high dose

DRUG

Placebo

placebo

DRUG

SAGE-217 low dose

low dose

Trial Locations (1)

10019

Sage Investigational Site, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY